Can Merck’s Keytruda Start Change In Lung Cancer Market?
Executive Summary
With approval of Merck’s PD-1 inhibitor Keytruda and PD-L1 companion diagnostic in the valuable lung cancer indication, Wall Street’s attention starts turning toward reimbursement and commercialization.
You may also be interested in...
Roche's Oncology Strategy: The Long Game Comes Into Focus
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.